Navigation Links
Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents
Date:5/20/2009

Other Presentations Highlight Pre-clinical Work of Company's Future Pro-healing Technologies

BARCELONA, Spain, May 20 /PRNewswire/ -- OrbusNeich announced today that two year follow up data from a single center, randomized clinical study in patients at high risk of restenosis were presented at EuroPCR 2009, demonstrating stable results in patients treated with the company's Genous Bio-engineered R stent, the world's first pro-healing stent, compared with results from patients treated with a drug-eluting stent.

Presented by Marcel Beijk, M.D., of the Academic Medical Center in Amsterdam, two year follow up data from the single center TRIAS HR (high risk) study show similar mortality (5.1% vs 4.2%) and target lesion revascularization (TLR) rates (15.3% vs 13.7%) for the Genous Bio-engineered R stent compared to Boston Scientific's Taxus(R) Liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% to 5.3%, with another event occurring at 658 days in a patient who had previously presented with a subacute thrombosis and who was on dual antiplatelet therapy at the time of both thromboses. There were no thrombotic events in the Genous treated group at any time period (0.0%). Myocardial infarctions (MI) increased from years one to two in the Taxus patients to 6.3%, while the MI rate in the Genous patients remained steady at 3.1%, all of which were peri-procedural.

"While both groups of patients showed good clinical outcomes, the Genous treated patients were relatively stable between one and two years," said Beijk.

TRIAS HR is a randomized, 193-patient, single-center, prospective study involving patients with a high risk of restenosis. High risk of restenosis is defined as patients who have diabetes mellitus and/or small vessels (less than or equal to 2.8 mm) and/or long lesions (greater than or equal to 23
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
2. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
3. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
4. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
5. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
6. New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
11. Cequent tkRNAi Technology to be Presented at the Centennial Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... -- , Safinamide significantly improves responder ... add-on to levodopa Safinamide is associated ... fluctuating PD patients as add-on to levodopa ... a research and development company focused on novel ... S.p.A., a pharmaceutical company strongly committed to the ...
(Date:6/18/2013)... June 18, 2013 Valeant Pharmaceuticals International, Inc. ... priced its previously announced public offering of common shares ... issue 23,529,412 common shares at a price of $85.00 ... billion. The Company will file a final prospectus supplement ... and will make a similar filing with the securities ...
(Date:6/18/2013)... ROCKY HILL, Conn. , June 18, 2013 ... many past clients of Alliance Seating and Mobility, ... now unable to access timely repair. This appears ... and a dramatic reduction of field service employees.  ... Unfortunately a great many of these clients ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Prices Public Offering Of Common Shares 2Valeant Pharmaceuticals Prices Public Offering Of Common Shares 3Valeant Pharmaceuticals Prices Public Offering Of Common Shares 4
... Calif., Aug. 31, 2011 Onyx Pharmaceuticals, ... it has appointed Helen Torley, M.B. Ch. B., M.R.C.P., ... her role, Dr. Torley will report to N. Anthony ... be responsible for all commercial activities related to Nexavar ...
... MOUNTAIN VIEW, Calif., Aug. 31, 2011 Concentric Medical, ... today announced that Stryker Corporation (NYSE: SYK ... Medical for $135 million in an all-cash transaction. The ... early in the fourth quarter of 2011. ...
Cached Medicine Technology:Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 2Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer 3STRYKER Signs Definitive Agreement to Acquire CONCENTRIC MEDICAL, Inc. 2
(Date:6/19/2013)... 2013 North American Seminars combines ... course with an online continuing education course ... occupational therapists. , The two day ... an online continuing education course will ... solving skills needed to evaluate and treat dizziness ...
(Date:6/19/2013)... MA (PRWEB) June 19, 2013 ... collaboration and sensor machine software, today announced it ... for its Decentralized Fusion Engine technology. The ... and the acquisition of key strategic partnerships. ... and wireless collaboration and machine-to-machine (M2M) software products ...
(Date:6/19/2013)... Francisco, CA (PRWEB) June 19, 2013 The ... sized tents is because users can place a 4x8 flood ... clearance boundary space to work around. In addition, Gorilla ... tents. Because they are the tallest, thickest and strongest grow ... new bar for grow tent standards. , Gorilla ...
(Date:6/19/2013)... Tornadoes and their devastating aftermath have increased across the ... to these deadly storms find it hard to recover. ... and corporations from natural and man-made disasters for over ... philosophy of providing a storm shelter that can be ... stand up, with light and a battery-operated blower for ...
(Date:6/19/2013)... DC (PRWEB) June 19, 2013 ... in the history of managed care. As many ... coverage through the new state-based and federally operated ... for essential health benefits, and examples of premium ... states, industry-leading health business information publisher Atlantic Information ...
Breaking Medicine News(10 mins):Health News:New Evidence Based Information on Treatment for Over 8 Million People in the U.S. Affected With Disorders of the Vestibular System 2Health News:Blueforce Awarded Patent for Decentralized Sensor Fusion 2Health News:Stealth Grow Tent Brand’s Popularity Rises 2Health News:Radius Engineering International Inc. Tornado-Resistant Storm Shelters 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2
... could help many avoid stroke , , THURSDAY, Jan. 24 (HealthDay ... for preventing strokes was stopped early because of excess bleeding, ... researchers said the trial could open the way to at ... seems to occur primarily in two groups of people -- ...
... Preserve Competition in Three Clinical Testing,Markets, WASHINGTON, ... that it will require Pearson Plc to divest ... to proceed with,Pearson,s proposed $950 million acquisition of ... originally proposed, would have,resulted in higher prices to ...
... of,Health and Human Services (HHS) Secretary Mike ... developed by the Healthcare Information,Technology Standards Panel ... three,of its "Interoperability Specifications" to help support ... Nationwide Health Information Network in,the United States ...
... disease ulcerative colitis are at increased risk of developing ... colleagues at Kanazawa University, Japan, identified a central role ... colon cancer in mice in which inflammation of the ... by repeated dextran sulfate sodium (DSS) ingestion. Expression of ...
... The U.S. Department of,Labor today announced a $1,250,000 ... to help provide assistance in paying health insurance,premiums ... for the,Health Coverage Tax Credit. The assistance is ... of 2002., "This $1.25 million grant will ...
... SCOTTSDALE, Ariz., Jan. 24 DC Ranch Village ... literally. The latest yoga class,Chocolate-Covered Yoga, teaches yogis how ... but also how to heighten the senses, and experience,sensations ... eating., The class is a very fulfilling yoga ...
Cached Medicine News:Health News:Anti-Clotting Drug Trial Shortened by Bleeding Problems 2Health News:Justice Department Requires Divestitures in Pearson's Acquisition of Harcourt Assessment 2Health News:Justice Department Requires Divestitures in Pearson's Acquisition of Harcourt Assessment 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 2Health News:HHS Secretary Recognizes Products of HITSP Standards Work 3Health News:HHS Secretary Recognizes Products of HITSP Standards Work 4Health News:U.S. Department of Labor Announces $1.25 Million to North Carolina to Help Trade-Affected Workers Pay for Health Insurance 2Health News:DC Ranch Village Health Club & Spa Twists with Chocolate Yoga Class 2
The CALBIOTECH, INC. (CBI), Mumps IgM ELISA tests system is an enzyme linked immunosorbent assay (ELISA) for the detection of IgM class antibodies to Mumps in human serum or plasma....
The DSL-05-10-MUG Mumps IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgG-class antibodies to Mumps Virus in human serum. This assay is intended for in...
... Xact stent is self-expanding and has a closed-cell ... flexible mesh intended to help restore the inner ... inner vessel surface, and potentially reduce the release ... when it is treated, which can lead to ...
... With BareWire technology, the wire crosses the ... delivery catheter. All other actions, including filter ... placement then occur over the wire., ,Emboshield ... break off during a carotid stenting procedure, ...
Medicine Products: